Molbio Diagnostics Limited
ListedMainboardHealthcare · NSE / BSE
Founded in 2000, Molbio Diagnostics Limited is a healthcare company focused on providing fast, accurate, and affordable diagnostic solutions for both infectious and non-communicable diseases. Its key product, the Truenat platform, is a portable PCR-based testing system that can deliver results within an hour, even in remote or low-resource areas, and is used to detect diseases like tuberculosis, COVID-19, hepatitis, HIV, and HPV. The company also offers radiology, digital pathology, and breast health screening solutions through its group entities and partners. It operates five manufacturing facilities across India to produce diagnostic devices, test kits, and portable X-ray systems. With a presence in over 80 countries and a strong distributor network, Molbio serves public health programs, hospitals, and diagnostic labs worldwide, generating revenue from both device sales and recurring test kit usage. As of March 31, 2025, the company had around 1,000 permanent employees along with over 1,500 contract workers.
Price Band
₹768 – ₹807
Issue Size
₹1164.62 L Cr
Lot Size
18 shares
GMP
₹116
+14.4%
Est. Listing
₹923
at current GMP
Subscribed
70.26x
overall
Open
10 Aug 2026
Close
12 Aug 2026
Allotment
13 Aug 2026
Refund
14 Aug 2026
Demat Credit
15 Aug 2026
Listing
17 Aug 2026
Last updated about 1 month ago
Overall Subscription
70.26x
Total Demand
QIB Multiplier
186.39x
Institutions & Funds
NII / HNI
49.80x
High Net-Worth
Retail (RII)
12.96x
Individual Bidders
Category-Wise Subscription Breakup
Live bidding breakdown by institutional, non-institutional, and retail investors
| Category | Shares Offered | Shares Applied / Bid | Times Subscribed |
|---|---|---|---|
| QIB | 2,325,146 | 433,382,148 | 186.39x |
| NIB | 1,743,859 | 86,840,604 | 49.80x |
| HNIs(10L +) | 1,162,573 | 59,076,594 | 50.82x |
| HNIs (2-10L) | 581,286 | 27,764,010 | 47.76x |
| RETAIL | 4,069,004 | 52,719,318 | 12.96x |
| EMPLOYEES | 20,520 | 272,466 | 13.28x |
| Total | 9,902,388 | 660,055,140 | 70.26x |
Application-Wise Breakup
Total unique applications received across retail and HNI tranches
| Category | Applications Reserved | Applications Received | Times Subscribed |
|---|---|---|---|
| RETAIL | 226,056 | 2,524,586 | 11.17x |
| EMPLOYEES | — | 8,879 | 0.00x |
| HNIs(10L +) | 4,613 | 46,455 | 10.07x |
| HNIs (2-10L) | 2,307 | 106,589 | 46.20x |
| Total Applications | 232,976 | 2,686,509 | 11.53x |
Day-Wise Subscription Progress
About Molbio Diagnostics Limited Public Issue & Market Profile
Molbio Diagnostics Limited is bringing an initial public offering (IPO) in the Healthcare sector with an aggregate issue size of ₹1,16,46,246 Crores. The shares are offered at a price band of ₹768 to ₹807 per equity share on NSE and BSE. Currently, market analysts recommend evaluating the company's financial valuation, price-to-earnings (P/E) multiple, and peer comparison prior to submitting bids.
Bidding & Quota Instructions:
The public offer consists of a fresh issue and offer-for-sale structured under SEBI regulations. Bidding is open to Qualified Institutional Buyers (QIB), Non-Institutional Bidders (NII/HNI), and Retail Individual Investors (RII). Applications can be submitted online using ASBA or UPI mandate through certified stock brokers and net banking portals.
Allotment Reconciliation Schedule:
Following the close of bidding on 2026-08-12, the basis of allotment is scheduled to be finalized on 2026-08-13. Investors can verify their application status online by submitting their PAN card number, Application Number, or DP Client ID on the registrar's official portal (Kfin Technologies Limited) or the BSE allotment checking window.
Frequently Asked Questions
What is the issue size and price band for Molbio Diagnostics Limited IPO?
The Molbio Diagnostics Limited IPO aggregate issue size is ₹1,16,46,246 Crores with an equity price band set at ₹768 to ₹807 per equity share. The retail lot size is 18 shares requiring a minimum capital outlay of approx. ₹14,526.
How can I check Molbio Diagnostics Limited IPO live subscription demand?
Live subscription figures are compiled real-time from the NSE and BSE bidding engines. You can track QIB, NII/HNI, and Retail category multiples directly on our dedicated live subscription page.
Where will Molbio Diagnostics Limited IPO allotment status be published?
The basis of allotment will be published on the official registrar portal (Kfin Technologies Limited) and the BSE status verification website on or around 2026-08-13.